cyclopentane has been researched along with Lymphoma, Mantle-Cell in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barth, MJ; Czuczman, MS; Czuczman, NM; Frys, SE; Gu, J; Hernandez-Ilizaliturri, FJ; Hu, Q; Klener, P; Liu, S; Mavis, C; Neppalli, V; Vockova, P | 1 |
1 other study(ies) available for cyclopentane and Lymphoma, Mantle-Cell
Article | Year |
---|---|
Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Separation; Cell Survival; Cyclopentanes; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Mice, SCID; NEDD8 Protein; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Rituximab; Small Molecule Libraries; Ubiquitins | 2016 |